CardioDx Receives $35,000,000 Series D Funding Round

  • Feed Type
  • Date
    12/18/2014
  • Company Name
    CardioDx
  • Mailing Address
    600 Saginaw Drive Redwood City, CA 94063 USA
  • Company Description
    Founded in 2004, CardioDx is a cardiovascular genomic diagnostics company. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
  • Website
    http://www.cardiodx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $35,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    The funds will enable CardioDx to broaden the commercial use of Corus CAD, the only clinically validated blood test that uses age, sex and gene expression to measure the likelihood of obstructive coronary artery disease in symptomatic patients, as well as to augment the company’s research efforts to improve healthcare quality and efficiency through the development of additional genomic tests for coronary artery disease.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy